United Therapeutics
(NASDAQ) UTHR
United Therapeutics Financials at a Glance
Market Cap
$25.00B
Revenue (TTM)
$3.18B
Net Income (TTM)
$1.33B
EPS (TTM)
$27.90
P/E Ratio
20.44
Dividend
$0.00
Beta (Volatility)
0.43 (Low)
Dividend
$0.00
Beta (Volatility)
0.43 (Low)
Price
$576.75
Volume
11,011
Open
$570.46
Price
$576.75
Volume
11,011
Open
$570.46
Previous Close
$570.40
Daily Range
$565.02 - $577.00
52-Week Range
$272.12 - $607.89
Dividend
$0.00
Beta (Volatility)
0.43 (Low)
Price
$576.75
Volume
11,011
Open
$570.46
Previous Close
$570.40
Daily Range
$565.02 - $577.00
52-Week Range
$272.12 - $607.89
UTHR News
Best Biotech ETFs to Buy in 2026
UTHR: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout United Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
1,400
CEO
Martine A. Rothblatt, PhD, MBA
Website
www.unither.comHeadquarters
Silver Spring, MD 20910, US
UTHR Financials
Key Financial Metrics (TTM)
Gross Margin
88%
Operating Margin
47%
Net Income Margin
42%
Return on Equity
20%
Return on Capital
20%
Return on Assets
17%
Earnings Yield
4.89%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$25.00B
Shares Outstanding
43.83M
Volume
11.01K
Avg. Volume
518.75K
Financials (TTM)
Gross Profit
$2.80B
Operating Income
$1.49B
EBITDA
$1.82B
Operating Cash Flow
$1.56B
Capital Expenditure
$520.50M
Free Cash Flow
$1.04B
Cash & ST Invst.
$1.56B
Total Debt
$0.00
United Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$790.20M
+7.4%
Gross Profit
$686.80M
+4.1%
Gross Margin
86.91%
N/A
Market Cap
$25.00B
N/A
Market Cap/Employee
$19.16M
N/A
Employees
1,305
N/A
Net Income
$364.30M
+20.9%
EBITDA
$524.30M
+23.6%
Quarterly Fundamentals
Net Cash
$1.56B
-47.5%
Accounts Receivable
$350.20M
+25.4%
Inventory
$183.10M
+16.0%
Long Term Debt
$0.00
N/A
Short Term Debt
$0.00
-100.0%
Return on Assets
16.94%
N/A
Return on Invested Capital
20.39%
N/A
Free Cash Flow
$173.30M
-31.9%
Operating Cash Flow
$346.20M
+1.5%